Evidence map›Paper›PMID 38915065›Full record

Trial reportArthritis research & therapy2024

Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial.

Katherine P Liao, Pamela Rist, Jon Giles, Leah Santacroce, Margery A Connelly, Robert J Glynn, Paul Ridker, Ahmed Tawakol, Joan Bathon, Daniel H Solomon

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arthritis research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02374021 (Treatments Against RA and Effect on FDG-PET/CT), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02374021 phase4completednot on this map

Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)

TypeinterventionalSponsorBrigham and Women's HospitalRan2016 to 2021Enrolled159ConditionsArthritis, RheumatoidArmsMethotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katherine P Liao *Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA. kliao@bwh.harvard.edu.
Pamela Rist *Department of Medicine, Harvard Medical School, Boston, MA, USA.
Jon GilesDivision of Rheumatology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Leah SantacroceDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA.
Margery A ConnellyLabcorp, Morrisville, NC, 27560, USA.
Robert J GlynnDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Paul RidkerDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Ahmed TawakolCardiology Division, Massachusetts General Hospital, Boston, MA, USA.
Joan BathonDivision of Rheumatology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Daniel H SolomonDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA.

Funding

Rheumatoid Arthritis and the Risk of Cardiovascular Disease: Biomarkers Risk Prediction and Underlying MechanismsR01HL163580 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$603k
NHLBI NIH HHS R01 HL163580NIAMS NIH HHS U01 AR068043NIH HHS NIH U01 AR068043
6 · The paper itself

Abstract

backgroundTreatments for rheumatoid arthritis (RA) are associated with complex changes in lipids and lipoproteins that may impact cardiovascular (CV) risk. The objective of this study was to examine lipid and lipoprotein changes associated with two common RA treatment strategies, triple therapy or tumor necrosis factor inhibitor (TNFi), and association with CV risk.

methodsIn this secondary data analysis of the TARGET trial, methotrexate (MTX) inadequate responders with RA were randomized to either add sulfasalazine and hydroxychloroquine (triple therapy), or TNFi for 24-weeks. The primary trial outcome was the change in arterial inflammation measured in the carotid arteries or aorta by FDG-PET/CT at baseline and 24-weeks; this change was described as the target-to-background ratio (TBR) in the most diseased segment (MDS). Routine lipids and advanced lipoproteins were measured at baseline and 24-weeks; subjects on statin therapy at baseline were excluded. Comparisons between baseline and follow-up lipid measurements were performed within and across treatment arms, as well as change in lipids and change in MDS-TBR.

resultsWe studied 122 participants, 61 in each treatment arm, with median age 57 years, 76% female, and 1.5 year median RA disease duration. When comparing treatment arms, triple therapy had on average a larger reduction in triglycerides (15.9 mg/dL, p = 0.01), total cholesterol to HDL-C ratio (0.29, p-value = 0.01), and LDL particle number (111.2, p = 0.02) compared to TNFi. TNFi had on average a larger increase in HDL particle number (1.6umol/L, p = 0.006). We observed no correlation between change in lipid measurements and change in MDS-TBR within and across treatment arms.

conclusionsBoth treatment strategies were associated with improved lipid profiles via changes in different lipids and lipoproteins. These effects had no correlation with change in CV risk as measured by vascular inflammation by FDG-PET/CT.

trial registrationClinicalTrials.gov ID NCT02374021.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidDrug Therapy, CombinationHydroxychloroquineLipidsMethotrexateAdultAgedFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographySulfasalazineTreatment OutcomeTumor Necrosis Factor InhibitorsAntirheumatic AgentsHydroxychloroquineLipidsMethotrexateSulfasalazineTumor Necrosis Factor InhibitorsCardiovascular diseaseLipidsRheumatoid arthritis

Identifiers

PMID38915065
PMCPMC11194931

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.